Table 2.
Comparisons of the baseline demographical, clinical, laboratory, and follow-up data between the patients who died and those who were discharged*
| Discharged (n=216) (Group A) |
Mortality (n=34) (Group B) |
ₐP | |
|---|---|---|---|
| Age (y) | 55.38+10.60 | 53.62+11.42 | 0.375 |
| Male | 140 (64.8) | 23 (67.6) | 0.747 |
| Previous history | |||
| Smoking | 62 (28.7) | 11 (32.4) | 0.664 |
| Diabetes mellitus | 74 (34.3) | 11 (32.4) | 0.827 |
| Hypertension | 153 (70.8) | 23 (67.6) | 0.705 |
| Family history of CAD | 93 (43.1) | 7 (20.6) | 0.013 |
| Admission heart rate (bpm) | 82.89+15.15 | 82.28+15.67 | 0.829 |
| Admission SBP (mm Hg) | 129.17+28.65 | 131.18+34.18 | 0.712 |
| Admission DBP (mm Hg) | 80.97+16.48 | 79.41+16.50 | 0.609 |
| LVEF (%) | 46.78+11.42 | 40.88+8.57 | 0.001 |
| Duration of hospitalization (d) | 7.00 (5.00) | 9.00 (7.30) | 0.002 |
| Diagnosis | 0.581 | ||
| NSTEMI | 59 (27.3) | 7 (20.6) | |
| STEMI | 83 (38.4) | 16 (47.1) | |
| UA | 74 (34.3) | 11 (32.4) | |
| Killip class on presentation | 0.024 | ||
| ≤I | 139 (64.4) | 15 (44.1) | |
| >I | 77 (35.6) | 19 (55.9) | |
| NYHA classification | 0.043 | ||
| ≤I | 76 (35.2) | 6 (17.6) | |
| >I | 140 (64.8) | 28 (82.4) | |
| Number of diseased vessels | 0.747 | ||
| 1 vessel | 76 (35.2) | 11 (32.4) | |
| >1 vessel | 140 (64.8) | 23 (67.6) | |
| Coagulation profile | |||
| PT (s)** | 14.00 (4.80) | 13.0 (5.50) | 0.827 |
| aPTT (s) ** | 35.50 (12.38) | 35.55 (12.05) | 0.874 |
| INR** | 1.25 (0.52) | 1.24 (0.46) | 0.693 |
| CBC profile | |||
| Hemoglobin (g/dL) | 12.38+1.44 | 13.12+2.41 | 0.088 |
| White blood cell count (×103/μL) | 10.03+2.79 | 13.33+4.33 | <0.001 |
| Neutrophils (×103/μL) | 7.37+0.95 | 7.59+0.98 | 0.196 |
| Lymphocytes (×103/μL) | 3.21+0.69 | 3.17+0.63 | 0.745 |
| Red blood cell count (×106/μL) | 4.28+0.58 | 4.20+0.57 | 0.478 |
| Hematocrit (%) | 37.83+5.77 | 39.72+7.41 | 0.162 |
| RDW (%)** | 15.70 (2.70) | 17.20 (2.89) | <0.001 |
| Platelet count (×103/μL) | 264+62.36 | 230.15+78.15 | 0.005 |
| MPV (fL) | 11.01+1.17 | 12.01+2.06 | <0.001 |
| Cardiac enzymes** | |||
| Troponin T** | 142 (65.7) | 23 (67.6) | 0.827 |
| CKMB** | 48.0 (41.0) | 45.91 (58.5) | 0.928 |
| CK | 190.25 (268.8) | 181.25 (408.8) | 0.732 |
| Follow-up | |||
| Rehospitalization | 35 (16.2) | 13 (38.2) | 0.002 |
| MI | 34 (15.7) | 12 (35.3) | 0.006 |
| Cardiogenic shock | 16 (7.4) | 8 (23.5) | 0.008 |
| Stroke | 15 (6.9) | 4 (11.8) | 0.304 |
| Dialysis | 4 (1.9) | 0 (0) | 0.555 |
| GI bleeding | 17 (7.9) | 2 (5.9) | 0.507 |
| Transfusion | 23 (10.6) | 6 (17.6) | 0.250 |
| CABG | 17 (7.9) | 9 (26.5) | 0.003 |
| Stent placement | 62 (28.7) | 11 (32.4) | 0.664 |
| Access-site complication | 1 (0.5) | 1 (2.9) | 0.254 |
CAD, Coronary artery disease; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; LVEF, Left ventricular ejection fraction; NSTEMI, Non ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; UA, Unstable angina; NYHA, New York Heart Association; PT, Prothrombin time; aPTT, Activated partial thromboplastin time; INR, International normalized ratio; CBC, Complete blood count; RDW, Red blood cell distribution width; MPV, Mean platelet volume; CKMB, Creatine kinase-MB CK, Creatine kinase; MI, Myocardial infarction; GI, Gastrointestinal bleeding; CABG, Coronary artery bypass grafting
Data are presented as means±SD, median (interquartile range)
, or n (%).